Dana-Farber/Boston Children's Cancer and Blood Disorders Center

What Dana-Farber/Boston Children's Cancer and Blood Disorders Center does

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is a joint pediatric oncology and hematology program operated as a collaboration between Dana-Farber Cancer Institute and Boston Children's Hospital, both Harvard Medical School teaching affiliates. It provides clinical care, research, and medical education focused on pediatric cancers (leukemia, lymphoma, brain tumors, solid tumors) and non-malignant blood disorders (sickle cell disease, thalassemia, bone marrow failure syndromes). The center operates through inpatient units at Boston Children's Hospital, the Jimmy Fund outpatient clinic, and ambulatory hematology/oncology clinics, supported by 150+ oncology and hematology specialists and an 18-slot fellowship pipeline.

The center's technology platform centers on CAR T-cell therapy, precision medicine and genomics-based approaches, hematopoietic stem cell transplantation (125+ procedures annually, including gene therapy trials), and a 200+ active clinical trial portfolio spanning Phase I-III studies, many of which are exclusive to the center. It runs specialty centers for brain tumors, blood disorders, hematologic malignancies, solid tumors, and adolescent and young adult oncology, and participates in research consortia including the Pediatric Brain Tumor Consortium, PNOC, CONNECT, Children's Oncology Group, and the DIPG ALL-In Consortium (for which it serves as the operations center).

Revenue is generated through direct patient care services (insurance-reimbursed inpatient and outpatient treatment, imaging, chemotherapy, radiation, and surgery), clinical trial operations including cooperative group and investigator-initiated studies, and stem cell transplantation. Patient acquisition runs through physician referrals, self-referrals, an online second opinion program, and International Patient Services with interpreter support in 60+ languages. Revenue is not publicly disclosed; the entity is a private non-profit academic medical program with no independent ownership structure, governed jointly by its two parent institutions.

Name

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Legal name

Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Website

https://danafarberbostonchildrens.org

Company type

Private

Operating status

Operating

Short description

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is a Harvard-affiliated pediatric oncology and hematology joint program providing clinical care, research, and fellowship training in childhood cancers and blood disorders, supported by 150+ specialists, 200+ active clinical trials, and a 125+ annual stem cell transplant program.

Ownership category

akta.pro rank

Product category

Pediatric Oncology and Hematology Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), General Medical and Surgical Hospitals (62211)

SIC

Services-Hospitals (8060), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Pediatric Hematology & Oncology (HLAKAFAE)

akta.pro secondary industries

Children’s Hospitals & Pediatric Health Systems (HLAFAJAG), Oncology & Cancer Specialty Hospitals (HLAFAHAC), Hematologic Oncology (Leukemia/Lymphoma/Myeloma) (HLAKAFAD)

Keywords

• Pediatric oncology care
• Hematology treatment services
• Pediatric stem cell transplant
• CAR T-cell therapy
• Pediatric clinical trials

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Patient Care Services: Revenue from direct patient care including inpatient treatment, outpatient clinics, diagnostic imaging, chemotherapy, radiation therapy, and surgical services for pediatric cancer and blood disorders
2. Clinical Trial Operations: Revenue from sponsoring and collaborating on clinical trials, including cooperative group trials and investigator-initiated studies
3. Stem Cell Transplants: Hematopoietic stem cell transplantation services for malignant and non-malignant conditions, including gene therapy trials

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels6 records

Core offering

Dana-Farber/Boston Children's Cancer and Blood Disorders Center is a joint pediatric oncology and hematology clinical program that provides comprehensive inpatient and outpatient treatment for children with cancer, leukemia, lymphoma, solid tumors, brain tumors, sickle cell disease, thalassemia, and other blood disorders. It delivers specialized therapies including CAR T-cell therapy, precision medicine, and stem cell transplantation, and operates over 200 active clinical trials along with fellowship training programs.

Product overview

Dana-Farber/Boston Children's Cancer and Blood Disorders Center operates as a unified pediatric oncology and hematology healthcare consortium offering comprehensive clinical services, innovative treatments, and medical education programs. The center provides over 200 active clinical trials, stem cell transplantation (125+ procedures annually), CAR T-cell therapy, and specialized treatment centers for brain tumors, blood disorders, hematologic malignancies, and solid tumors. The organization also runs the Pediatric Hematology/Oncology Fellowship Program (three-year training) and an advanced Pediatric Neuro-Oncology Clinical Fellowship (one-year), educating future leaders in the field. Patient services include international patient services with 50+ language interpreters, online second opinions, and survivorship programs. The center integrates with MyChildren's Patient Portal for patient access and uses Google Translate for website accessibility.

Differentiator

Problem solved

Functional benefit

Products and services

• Stem Cell Transplant Program

Quantifiable outcome

• 125+ stem cell transplants performed annually
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and major.

• Boston Children's HospitalcoreStrategic or Co-development PartnerJoint venture partnership combining pediatric oncology and hematology services. Boston Children's provides inpatient facilities, surgical services, and comprehensive pediatric subspecialty care including intensive care, cardiology, neurology, and other supporting services.
• Dana-Farber Cancer InstitutecoreStrategic or Co-development PartnerPrimary partner providing cancer care expertise, research capabilities, and adult oncology resources. Shared faculty appointments and integrated clinical operations.
• Harvard Medical SchoolcoreStrategic or Co-development PartnerTeaching affiliate of Harvard Medical School. Faculty hold appointments at Harvard Medical School. Fellows receive training affiliated with Harvard.
• National Cancer Institute (NCI)coreStrategic or Co-development PartnerNCI-designated Cancer Center providing research support, clinical trial infrastructure, and access to national research networks and cooperative groups.
• Broad InstitutemajorStrategic or Co-development PartnerResearch collaboration for genomics and computational biology. Faculty including Dr. Kimberly Stegmaier hold Institute Member positions at Broad Institute.
• Pediatric Brain Tumor Consortium (PBTC)majorStrategic or Co-development PartnerMember of the Pediatric Brain Tumor Consortium for collaborative clinical trials and research on pediatric brain tumors.
• Pediatric Neuro-Oncology Consortium (PNOC)majorStrategic or Co-development PartnerMember of PNOC for collaborative neuro-oncology clinical trials and research.
• Collaborative Network for Neuro-oncology Clinical Trials (CONNECT)majorStrategic or Co-development PartnerMember of CONNECT for neuro-oncology clinical trial collaboration.
• DIPG ALL-In ConsortiumcoreStrategic or Co-development PartnerOperations Center for the first DIPG-specific consortium focused on diffuse intrinsic pontine glioma research and treatment.
• Children's Oncology Group (COG)majorStrategic or Co-development PartnerActive participant in Children's Oncology Group clinical trials for childhood cancers.
• Whitehead Institute at MITmajorTechnology or IntegrationResearch collaboration for stem cell biology and gene therapy development. Dr. David Williams completed research training here.
• NovartismajorStrategic or Co-development PartnerNovartis-BCH/DFCI Pediatric Hematology/Oncology Early Oncology Drug Development Fellowship Program - one-year training opportunity in early drug development.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Nationwide Children's Hospital – The Center for Childhood Cancer and Blood Diseases: Comprehensive pediatric cancer and blood disease program with significant research capacity and clinical trial participation. Comparable in patient population, treatment modalities, and academic medical center affiliation.
• Seattle Children's Hospital – Cancer and Blood Disorders Center: Top-tier pediatric oncology and hematology center with strong research and clinical trial programs. Comparable in target patient population, treatment scope, and academic affiliation.
• Texas Children's Hospital Cancer and Hematology Centers: One of the largest pediatric cancer programs in the U.S., offering comprehensive hematology/oncology, stem cell transplant, and CAR T-cell therapy. Comparable in service scope, trial volume, and pediatric specialty capabilities.
• UCSF Benioff Children's Hospitals – Pediatric Hematology/Oncology: Academic pediatric oncology and hematology program with active clinical research and CAR T-cell/gene therapy initiatives. Comparable in university-based specialist care and clinical trial programs.
• Children's Healthcare of Atlanta – Aflac Cancer and Blood Disorders Center: Large pediatric hematology/oncology program serving a high-volume patient base with strong research and clinical trial offerings. Comparable in service breadth, transplant capabilities, and pediatric subspecialty centers.
• St. Jude Children's Research Hospital: The leading U.S. pediatric cancer research and treatment center, operating as a major destination for complex pediatric oncology and hematology cases. Directly comparable in mission (research-driven pediatric cancer care), scale of clinical trials, and CAR T-cell/gene therapy capabilities.
• Children's Hospital of Philadelphia (CHOP) Cancer Center: Top-ranked pediatric cancer program competing with Dana-Farber/Boston Children's for national referrals, complex cases, and clinical trial leadership. Comparable in pediatric oncology/hematology service breadth, research output, and fellowship training.
• Cincinnati Children's Hospital Medical Center – Cancer & Blood Diseases Institute: Major pediatric hematology/oncology program with substantial research portfolio and clinical trial enrollment. Directly comparable in pediatric cancer and blood disorder care, including stem cell transplantation.

Broad incumbents

• Johns Hopkins Pediatric Oncology: Established pediatric oncology program with a strong research base and active clinical trials. Comparable in academic/specialty care mix but operates within a broader general academic medical center.
• Memorial Sloan Kettering Cancer Center – Pediatric Oncology: While primarily an adult oncology center, MSK's pediatric program is a major destination for complex pediatric cancer cases. Comparable in clinical trial capabilities and precision medicine but operates at a broader institutional scale with mixed adult/pediatric focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dana-Farber/Boston Children's Cancer and Blood Disorders Center